David Attwood
Director of Finance/CFO bij THCinol/CBDinol CanPharma GmbH
Profiel
David Attwood is currently the Chief Financial Officer at THCinol.
Prior to this, he was the Chief Executive Officer at Health House International Ltd.
from 2021 to 2023.
Mr. Attwood is a graduate of The University of Nottingham and holds an MBA from Instituto de Estudios Superiores de la Empresa.
Actieve functies van David Attwood
Bedrijven | Functie | Begin |
---|---|---|
THCinol/CBDinol CanPharma GmbH
THCinol/CBDinol CanPharma GmbH Pharmaceuticals: OtherHealth Technology Part of CanPharma GmbH /Jacker/, THCinol/CBDinol CanPharma GmbH is a German company that brings years of experience in the treatment with cannabinoids and necessary expertise to ensure a professional handling of medical cannabis. The private company is based in Oranienburg, Germany. The company aims to fully unleash the potential of medical cannabis with a focus on the well-being of the patient. The company offers quality products, specialized information, and a CanPharma patient ID. The company was founded by Holger Sprengel and Henrik Arne Sprengel, with Henrik Arne Sprengel serving as CEO since incorporation. THCinol/CBDinol CanPharma was acquired by CanPharma GmbH /Jacker/ from Health House International Ltd. on November 16, 2022. | Director of Finance/CFO | - |
Eerdere bekende functies van David Attwood
Bedrijven | Functie | Einde |
---|---|---|
HEALTH HOUSE INTERNATIONAL | Chief Executive Officer | 19-03-2023 |
Opleiding van David Attwood
The University of Nottingham | Graduate Degree |
Instituto de Estudios Superiores de la Empresa | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Health House International Ltd.
Health House International Ltd. Pharmaceuticals: OtherHealth Technology Health House International Ltd. engages in the distribution of medicinal cannabis. The company was founded by Jason Peterson and Harry Karelis in 2014 and is headquartered in Melbourne, Australia. | Health Technology |
THCinol/CBDinol CanPharma GmbH
THCinol/CBDinol CanPharma GmbH Pharmaceuticals: OtherHealth Technology Part of CanPharma GmbH /Jacker/, THCinol/CBDinol CanPharma GmbH is a German company that brings years of experience in the treatment with cannabinoids and necessary expertise to ensure a professional handling of medical cannabis. The private company is based in Oranienburg, Germany. The company aims to fully unleash the potential of medical cannabis with a focus on the well-being of the patient. The company offers quality products, specialized information, and a CanPharma patient ID. The company was founded by Holger Sprengel and Henrik Arne Sprengel, with Henrik Arne Sprengel serving as CEO since incorporation. THCinol/CBDinol CanPharma was acquired by CanPharma GmbH /Jacker/ from Health House International Ltd. on November 16, 2022. | Health Technology |